Cargando…

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients

PURPOSE: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well as their safety and efficacy. PATIENTS AND METHODS: A total of 50 patients with advanced HCC received sintilimab (200 mg) plus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wen, Gong, Caifeng, Peng, Xuenan, Bi, Xinyu, Sun, Yongkun, Zhou, Jianguo, Wu, Fan, Zeng, Huiying, Wang, Yan, Zhou, Hui, Zhao, Hong, Cai, Jianqiang, Zhou, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662860/ https://www.ncbi.nlm.nih.gov/pubmed/35275208 http://dx.doi.org/10.1158/1078-0432.CCR-21-3972

Ejemplares similares

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
por: Zeng, Xianghua, et al.
Publicado: (2023)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
por: Chen, Li, et al.
Publicado: (2022)

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
por: Han, Xiao, et al.
Publicado: (2022)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
por: Bando, Hideaki, et al.
Publicado: (2022)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
por: Nowakowski, Grzegorz S., et al.
Publicado: (2022)

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
por: Yukami, Hiroki, et al.
Publicado: (2022)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
por: Long, Georgina V., et al.
Publicado: (2021)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
por: Song, Yuqin, et al.
Publicado: (2022)

Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
por: Zhang, Zhanjie, et al.
Publicado: (2022)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
por: Manji, Gulam A., et al.
Publicado: (2021)

A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
por: Hanes, Vladimir, et al.
Publicado: (2018)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
por: Zhang, Wen, et al.
Publicado: (2021)

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
por: West, Howard Jack, et al.
Publicado: (2022)

B7 score and T cell infiltration stratify immune status in prostate cancer
por: Zhou, Qianghua, et al.
Publicado: (2021)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021)

Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
por: Miller, Katherine E., et al.
Publicado: (2022)

Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
por: Regan, Daniel P., et al.
Publicado: (2022)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fe9it1ut0fdg2oss5jmdqbfmv9